Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSO-021 in Malignant Pleural Effusion and Mesothelioma
NCT05278975Phase 2Completed
- Sponsor
- RS Oncology
- Start
- Mar 2022
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RSO-021 in malignant pleural effusion (MPE), mesothelioma, solid tumor, sponsored by RS Oncology. Started Mar 2022; status: completed.
02
Drugs
RSO-021
03
Conditions
malignant pleural effusion (MPE)mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT05278975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278975.